CIDP Treated With Plasma-Derived Therapy
... Patients with rare, chronic inflammatory demyelinating polyneuropathy (CIDP) depend on plasma donation ANNAPOLIS, Md. , April 24 /PRNewswire/ -- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating, progressive neurological disorder that results ...NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch ...NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch ...GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director
... the only non-profit organization dedicated to serving patients afflicted with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and variants, announced the appointment of Patricia A. Bryant to the position of Executive Director effective as of May 2009. Patricia ...New Jefferson study may redefine how a chronic auto-immune disease is diagnosed
... PHILADELPHIA New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and ...NORD to Honor Rare Disease Pioneers
... Talecris Biotherapeutics, Inc., for developing Gamunex(R), the first therapy approved for treating people with chronic inflammatory demyelinating polyneuropathy ViroPharma, Inc., for making available to patients Cinryze(R), the first drug approved by FDA to prevent swelling that occurs in various body ...Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP
... of the health-related quality of life results from the largest clinical trial ever conducted in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the April 14, 2009 issue of Neurology . The data demonstrate that long-term treatment with Gamunex (Immune Globulin Intravenous (Human), ...Type of vitamin B1 could treat common cause of blindness
... trials have shown that benfotiamene is absorbed better than thiamine [the most common form of vitamin B1] and significantly improved diabetic polyneuropathy in patients, and it's already taken as a supplement for diabetic complications," Ramana said. ...NeurogesX Reports Fourth Quarter and Year-End 2008 Results
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate Qutenza(TM), a dermal ...NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
... study involving 307 patients with painful HIV-associated distal sensory polyneuropathy (HIV-DSP) receiving a single application of NGX-4010, a high-concentration ... pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage ...Immunosyn Corporation Releases SF-1019 Study Results
... review included but were not limited to Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy (RSD or RSDS). The summary ... (MS) and neurological disorders such as Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more ...NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch ...NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch ...NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
... from study C119, its second Phase 3 clinical trial of NGX-4010, the Company's dermal patch drug candidate, in patients with HIV-distal sensory polyneuropathy (HIV-DSP). The prespecified analysis of the primary endpoint, comparing all patients treated with NGX-4010 compared to all patients treated with the ...NeurogesX Receives European Commission Approval for Qutenza(TM)
... in cases of postherpetic neuralgia (PHN) and painful HIV-distal sensory polyneuropathy (HIV-DSP), or diseases, such as diabetes. An estimated 8% of the ... pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage ...NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
... in cases of postherpetic neuralgia (PHN) and painful HIV-distal sensory polyneuropathy (HIV-DSP), or diseases, such as diabetes. An estimated 8% of the ... pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage ...NeurogesX Reports Second Quarter 2008 Results
... studies of NGX-4010 in other indications (e.g., HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN), where it is likely that ... pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage ...Immunosyn Corporation Files 10-Q
... including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other ... (MS) and neurological disorders such as Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). The ...Immunosyn Corporation Announces 2007 Results, Files 10KSB
... including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other ... (MS) and neurological disorders such as Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). The ...Immunosyn Corporation to Present at FSX
... including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other ... (MS), neurological disorders such as Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and ...NeurogesX Reports Second Quarter 2009 Results
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch ...NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch ...NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza((TM)), a dermal ...NeurogesX Added to Russell 3000 Index
... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch ...